CRIS Current Research Information System

PANTANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.136
NA - Nord America 4.241
EU - Europa 2.932
AF - Africa 348
SA - Sud America 263
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.181
VN - Vietnam 1.690
CN - Cina 1.266
SG - Singapore 1.208
IT - Italia 764
GB - Regno Unito 498
DE - Germania 353
SE - Svezia 337
HK - Hong Kong 279
IN - India 192
FR - Francia 188
BR - Brasile 183
NL - Olanda 162
KR - Corea 159
RU - Federazione Russa 133
CI - Costa d'Avorio 131
IE - Irlanda 110
FI - Finlandia 94
JP - Giappone 67
ZA - Sudafrica 66
TG - Togo 60
SC - Seychelles 57
UA - Ucraina 57
PH - Filippine 46
AR - Argentina 36
BD - Bangladesh 36
AT - Austria 34
EE - Estonia 33
BG - Bulgaria 32
CA - Canada 32
CH - Svizzera 29
TH - Thailandia 28
BE - Belgio 26
JO - Giordania 23
PL - Polonia 23
MX - Messico 22
ES - Italia 18
ID - Indonesia 18
TW - Taiwan 18
IQ - Iraq 17
NG - Nigeria 15
TR - Turchia 15
AU - Australia 14
EC - Ecuador 14
IR - Iran 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 11
CL - Cile 10
CO - Colombia 7
MY - Malesia 7
UZ - Uzbekistan 7
PK - Pakistan 6
EG - Egitto 5
LB - Libano 5
RO - Romania 5
DZ - Algeria 4
LT - Lituania 4
NP - Nepal 4
PT - Portogallo 4
VE - Venezuela 4
KZ - Kazakistan 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
TN - Tunisia 3
AL - Albania 2
AZ - Azerbaigian 2
CY - Cipro 2
GE - Georgia 2
GH - Ghana 2
GR - Grecia 2
GT - Guatemala 2
IL - Israele 2
KH - Cambogia 2
NO - Norvegia 2
OM - Oman 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HR - Croazia 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 12.933
Salva come PNG Salva come JPEG
Città #
Singapore 841
Ashburn 557
Chandler 417
Ho Chi Minh City 404
Southend 398
Fairfield 331
Hefei 331
Hanoi 326
Hong Kong 268
Bologna 231
San Jose 195
Woodbridge 163
Seoul 150
Beijing 149
Ann Arbor 148
Seattle 143
Dallas 141
Wilmington 138
Dong Ket 136
Houston 136
Abidjan 131
Cambridge 115
Dublin 110
Princeton 109
Santa Clara 101
Boardman 83
New York 80
Lauterbourg 76
Los Angeles 75
Helsinki 68
Lomé 60
Haiphong 59
Milan 57
Tokyo 54
Nanjing 46
Bremen 45
Munich 41
Hyderabad 40
Da Nang 39
Frankfurt am Main 39
Council Bluffs 38
Westminster 38
Padova 33
Sofia 32
Turin 31
Jinan 30
Bengaluru 29
Berlin 27
Buffalo 27
Redmond 27
Brussels 25
Guangzhou 25
Jacksonville 25
Redondo Beach 25
San Diego 24
Amman 23
Changsha 23
Shenyang 23
Amsterdam 22
Fabriano 22
Redwood City 22
São Paulo 22
Vienna 22
Saint Petersburg 21
Bern 20
Can Tho 20
Chicago 20
Nuremberg 20
Johannesburg 19
Biên Hòa 18
Florence 18
Lappeenranta 18
Ha Long 17
Quận Bình Thạnh 17
Zhengzhou 17
Nanchang 16
Tianjin 16
Thái Nguyên 15
Abeokuta 14
Hải Dương 14
London 14
Medford 14
Rome 14
Shanghai 14
Falkenstein 13
Ninh Bình 13
Toronto 13
Warsaw 13
Wuhan 13
Atlanta 12
Hebei 12
Washington 12
Bắc Ninh 11
Dhaka 11
Falls Church 11
Jakarta 11
Paris 11
Shenzhen 11
Tongling 11
Điện Bàn 11
Totale 8.191
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 338
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 265
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 246
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 232
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 227
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 220
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 218
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 218
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 211
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 204
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 204
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 197
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 197
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 194
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 191
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 182
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 182
Thalidomide maintenance in multiple myeloma: certainties and controversies. 180
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 177
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 175
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 174
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 174
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 172
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 172
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 171
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 169
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 162
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 153
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 147
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 143
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 143
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 143
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 142
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 141
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 135
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 134
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 134
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 132
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 130
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 129
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 127
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 120
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 117
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 113
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 107
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 104
null 98
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 97
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 92
Proteasome inhibitors: Bortezomib in multiple myeloma 91
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 88
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 81
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 76
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 74
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 74
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 70
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 70
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 61
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 58
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 51
Totale 13.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021372 0 0 0 0 0 0 0 0 0 33 31 308
2021/20221.192 136 52 60 93 89 51 27 82 48 136 208 210
2022/20231.597 141 222 63 262 108 134 46 97 269 54 121 80
2023/2024603 41 83 34 51 47 152 27 83 13 19 31 22
2024/20251.973 113 193 172 173 207 78 144 68 51 228 177 369
2025/20265.380 538 1.031 461 455 516 281 504 175 1.063 356 0 0
Totale 13.183